$Novo-Nordisk A/S (NVO.US)$ & $Eli Lilly and Co (LLY.US)$ 's...

$Novo-Nordisk A/S(NVO.US)$ & $Eli Lilly and Co(LLY.US)$ 's MCap increased by $285 bil in Q1 2024 alone, driven mostly by growth of the GLP-1 franchises,
Revenue from both companies GLP-1 drugs totaled $33.6 bil last yr, an impressive number that almost certainly will grow this yr,
But let's put that $285 bil incr in mkt value into perspective,
$AbbVie(ABBV.US)$ has a $315 bil MCap, not much bigger than the combined Q1 incr in mkt value for LLY & NVO,
ABBV had $54 bil in revenue in 2023, compared to total product revenue of $34.1 bil for LLY and $33.7 bil for NVO,
And this is just looking at the Q1 24 increase in value, LLY and NVO have both more than doubled over the last yr,
I definitely wouldn't want to short either of these stocks, but markets have already priced in a lot of future growth for LLY & NVO